ABsTRAcT As the duration of bronchoconstriction induced by inhaled histamine phosphate is greater than five minutes, a study was carried out to determine whether this leads to a cumulative effect when histamine is inhaled at five minute intervals as in standardised procedures. Fourteen clinically stable adult asthmatic subjects were studied. In the first part of the study (the noncumulative stage) they inhaled doubling concentrations of histamine until appreciable bronchoconstriction occurred (changes close to 50% in lung resistance for seven subjects and 15% in forced expiratory volume in one second for seven others 
ABsTRAcT As the duration of bronchoconstriction induced by inhaled histamine phosphate is greater than five minutes, a study was carried out to determine whether this leads to a cumulative effect when histamine is inhaled at five minute intervals as in standardised procedures. Fourteen clinically stable adult asthmatic subjects were studied. In the first part of the study (the noncumulative stage) they inhaled doubling concentrations of histamine until appreciable bronchoconstriction occurred (changes close to 50% in lung resistance for seven subjects and 15% in forced expiratory volume in one second for seven others). After functional recovery the last concentration of histamine was nebulised on two more occasions, allowing for functional recovery after each nebulisation. In the second part of the study (the cumulative stage) subjects inhaled, depending on their responsiveness, three to eight consecutive doses of the histamine concentration last administered in the non-cumulative stage, these doses being administered at five minute intervals, without recovery. The cumulative effect was assessed by linear regression analysis of the changes in the specific functional indices, all the values obtained during the non-cumulative stage being given the score 0 and those obtained during the cumulative step scores of 1, 2, etc. In all but one instance significant (p < 0.01) correlations were obtained and the slopes were positive, thus showing a cumulative effect. It period of recovery between each nebulisation.) To evaluate the possible cumulative effect, the last concentration of histamine used in the noncumulative challenge was then nebulised at five minute intervals, with no functional recovery allowed, for three to eight doses, depending on the severity of each subject's airways obstruction and symptoms.
MEASUREMENTS
Solutions of histamine were inhaled through the Wright nebuliser (output 0*14 m/min; flow rate 1min; mean mass diameter of inhaled particles 1-3 ,um'°). Histamine was inhaled by the subjects breathing at ordinary tidal volume, using an orofacial mask for two minutes. Baseline spirometric measurements were made with a Collins 9 litre water spirometer.
In seven subjects (1-7), bronchoconstriction was assessed by measurement of RL and thoracic gas volume (TGV), from which specific lung conductance (sGL) was derived. RL was monitored every minute up to five minutes in both the cumulative and the non-cumulative phases of the study. It was also assessed approximately every five minutes thereafter until recovery in the non-cumulative part of the study. TGV was measured two to three minutes after the end of nebulisation and every five minutes thereafter until recovery, in the non-cumulative stage.
In the seven other subjects (8-14) the response was assessed by measuring FEV, with the Collins spirometer. In the non-cumulative stage the FEV, was measured 30, 90, and 180 seconds after the end of each nebulisation and every three minutes thereafter until recovery. In the cumulative part of the Tremblay, Lemire, Ghezzo, Pineau, Martin, Cartier, Malo study it was measured 30, 90, and 180 seconds after the end of each nebulisation.
RL and TGV were measured in a flow displacement body plethysmograph." Pleural pressure was estimated from a 10 cm oesophageal balloon'2 connected to a Validyne differential pressure transducer via a 100 cm polyethylene catheter. The other side of the transducer was connected to an oral pressure tap to estimate transpulmonary pressure. RL was measured as the ratio of change in transpulmonary pressure to change in buccal flow during tidal breathing. TGV was assessed by asking the subjects to pant three or four times in two to four seconds while a shutter was closed at the end of a normal expiration.
ANALYSIS OF RESULTS
At each histamine concentration the percentage change in the functional indices was calculated from the following formula: highest RL posthistaminehighest RL after PBS/highest RL after PBS in the case of measurements obtained for RL. For sGL and FEVI the formula was: lowest value after histamine -lowest value after PBS/lowest value after PBS. Dose response curves were drawn on a semi logarithmic graph, the non-cumulative histamine Histamine phosphate has a cumulative effect when inhaled at five minute intervals Figures 1 and 2 show for each individual the percentage change in RL and sGL after each nebulisation of the non-cumulative and cumulative challenges in subjects 1-7. Figure 3 gives the same information for FEV, for the seven other subjects (8) (9) (10) (11) (12) (13) (14) . The ranges of percentage change in RL, sGL, and FEVI obtained at the first nebulisation of the non-cumulative stage were 16-7-291-5, 18-4-77-7, and 15-1-22-4. It can be seen that the changes obtained in the cumulative challenge steadily increase and reach values beyond 2 SD of the mean of the four values of the non-cumulative step in all instances for RL and FEV, and in six out of seven instances for sGL. Table 2 gives the corresponding statistical analysis using the regression analysis. All the non-cumulative values were given the score 0 and the cumulative values scores 1, 2, etc. The regression analysis showed highly significant (p < 0.01) correlation coefficients (except for subject 3 in the case of sGL) and positive slopes, thus confirming the cumulative effect. In the subjects for whom more than three points were determined in the cumulative part of the study the slopes were similar to those calculated with all the points (non-Tremblay, Lemire, Ghezzo, Pineau, Martin, Cartier, Malo cumulative and cumulative steps), thus confirming the representativity of these slopes.
Discussion
Our study shows that histamine has a cumulative bronchoconstriction effect when inhaled at five minute intervals once significant bronchoconstriction has been reached. These results could have been predicted, on the grounds that the time course of the bronchoconstriction secondary to histamine is generally beyond five minutes.56 Juniper et al7 found that PC20FEV, obtained from a standard doseresponse curve was not significantly different from the value extrapolated by giving only the last concentration used in the standard dose-response curve. This suggested that histamine had no cumulative effect when the PC20FEV, is the index used to assess the response. Even if PC20FEV, does not seem to be affected significantly by consecutive nebulisations of histamine at five minute intervals, this does not exclude the possibility that histamine has a cumulative effect when other means of assessing the bronchoconstrictor response are used. In our study we assessed the percentage change of the physiological parameter from the post PBS value after each histamine inhalation. PC20FEV, might not be affected by the cumulative effect of histamine as it is an index which lacks sensitivity by comparison with other indices used to assess the bronchoconstrictor response,'4 whose reproducibility between two assessments is 10-1 6'4 15 single twofold concentration differences. This range of reproducibility may preclude a satisfactory assessment of any cumulative effect. Juniper's results and ours can be reconciled in the following way: histamine has a cumulative effect when inhaled at five minute intervals, but this does not significantly affect PC20FEV, results.
Even if forced expiratory manoeuvres can induce bronchodilation in the presence of induced bronchoconstriction, '6-19 The cumulative effect of histamine when inhaled at five minute intervals could be explained in two ways. A pharmacological cumulative effect could be induced as each concentration is added to the previous one without the latter being completely metabolised. The other cumulative effect is linked with airway calibre. Once significant bronchoconstriction is induced, any further decrease in airway calibre causes an even greater change in airflow obstruction, as resistance is inversely proportional to the fourth power of the radius in laminar flow conditions. 2 Should dose-response curves for histamine be expressed on a cumulative or on a non-cumulative scale? Even if our study shows that histamine has a cumulative effect when inhaled at five minute intervals, we have reason to suspect that the degree of this cumulative effect is not important. Firstly, the value of PC20, which is most often expressed on a non-cumulative scale,3 may vary by a single twofold concentration even in the case of a full pharmacological cumulative effect and is not significantly influenced by this cumulative effect.7 In the case of a full pharmacological additive effect all the concentrations from 0-03 to 16 mg/ml would total 32 mg/ ml of inhaled histamine if the results were expressed on a cumulative scale. The difference between 16 mg/ml and 32 mg/ml is within the reproducibility range of the test.'4" Secondly, the physiological cumulative effect mentioned above would apply only when significant bronchoconstriction is reached, as was the case with the protocol used in the present study. The possibility that a cumulative effect might be noticed at lower concentrations not causing significant bronchoconstriction remains to be explored. Thus the physiological cumulative effect might only be present once significant bronchoconstriction is reached and not for the complete scale of the dose-response curves. It has been proposed" that the results of provocative inhalation tests for histamine should be expressed in a cumulative way. This, however, would assume a completely cumulative effect, which is unlikely for the reasons mentioned. To express histamine dose-response curves in a cumulative way rather than on a noncumulative scale seems imprecise. Other studies are needed to quantify the degree of the cumulative effect.
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